Focused On-demand Library for CD226 antigen

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q15762

UPID:

CD226_HUMAN

Alternative names:

DNAX accessory molecule 1

Alternative UPACC:

Q15762; B2R818

Background:

The CD226 antigen, also known as DNAX accessory molecule 1, plays a pivotal role in immune response regulation. It is crucial for intercellular adhesion, lymphocyte signaling, cytotoxicity, and lymphokine secretion by cytotoxic T-lymphocyte (CTL) and NK cells. CD226 serves as a cell surface receptor for NECTIN2, facilitating T-cell proliferation and cytokine production, including IL2, IL5, IL10, IL13, and IFNG. It also competes with PVRIG for NECTIN2 binding, highlighting its significance in immune modulation.

Therapeutic significance:

Understanding the role of CD226 antigen could open doors to potential therapeutic strategies. Its involvement in key immune processes suggests that targeting CD226 could offer novel approaches for enhancing immune response against various diseases.